Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphoadenopathy syndrome (LAS). 1987

R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
Department of Allergology and Clinical Immunology, University of Rome La Sapienza, Italy.

The complement system was examined in 16 patients with AIDS-related complex (ARC) (n = 5) and/or lymphoadenopathy syndrome (LAS) (n = 11). Of these patients 62.5% showed an impairment of classical and/or alternative pathway activity associated with the presence of cleavage fragments of C3 and/or B and a significant reduction of many complement factors. The data indicate pathological complement activation in these patients through the classical and/or alternative pathway. Complement activation was more severe in patients with ARC than in those with LAS, and greater in drug abusers than homosexuals. The lack of efficient complement in the patients can be considered an 'acquired complement deficiency' with possible importance in the failure to combat the HIV attack.

UI MeSH Term Description Entries
D008297 Male Males
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative
D003171 Complement Pathway, Classical Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Classical Complement Pathway,Classical Complement Activation Pathway,Complement Activation Pathway, Classical
D005260 Female Females
D006461 Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity. Haemolysis,Extravascular Hemolysis,Intravascular Hemolysis,Extravascular Hemolyses,Haemolyses,Hemolyses, Extravascular,Hemolyses, Intravascular,Hemolysis, Extravascular,Hemolysis, Intravascular,Intravascular Hemolyses
D006716 Homosexuality The sexual attraction or relationship between members of the same SEX. Homosexuality, Ego-Dystonic,Ego-Dystonic Homosexuality,Homosexuality, Ego Dystonic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
February 1988, Minerva medica,
R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
March 1989, Catheterization and cardiovascular diagnosis,
R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
January 1987, Doklady Akademii nauk SSSR,
R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
January 1994, Scandinavian journal of infectious diseases,
R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
January 1984, Transactions of the Association of American Physicians,
R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
July 1985, Clinical chemistry,
R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
January 1988, Cancer detection and prevention,
R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
December 1987, European journal of epidemiology,
R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
January 1984, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
R Perricone, and L Fontana, and C de Carolis, and C Carini, and M C Sirianni, and F Aiuti
July 1987, Journal of clinical & laboratory immunology,
Copied contents to your clipboard!